Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia

Sirinya Teeraananchai1,2, Matthew Law3, David Boettiger3, Nicole De La Mata4, Nikhil Gupte5, Yun-ting Lawrence Chan6, Thach Ngoc Pham7, Romaneex Chaiwarith8,9, Penh Sun Ly10, Yu-Jiun Chan11, Sasisopin Kiertiburanakul12, Suwimon Khusuwan13, Fujie Zhang14, Evy Yuniastuti15, Nagalingeswaran Kumarasamy16, Sanjay Pujari17, Iskandar Azwa18, I Ketut Agus Somia19, Junko Tanuma20, Rossana Ditangco21, Jun Yong Choi22, Oon Tek Ng23, Cuong Duy Do24, Yasmin Gani25, Jeremy Ross26, Awachana Jiamsakul3 and the TREAT Asia HIV Observational Database (TAHOD) of IeDEA Asia-Pacific

Abstract

Introduction: Viral load (VL) testing is still challenging to monitor treatment responses of antiretroviral therapy (ART) for HIV treatment programme in Asia. We assessed the association between routine VL testing and virological failure (VF) and determine factors associated with switching to second-line regimen.

Methods: Among 21 sites from the TREAT Asia HIV Observational Database (TAHOD), people living with HIV (PLHIV) aged ≥18 years initiating ART from 2003 to 2021 were included. We calculated the average number of VL tests per patient per year between the date of ART initiation and the most recent visit. If the median average number of VL tests was ≥0.80 per patient per year, the site was classified as a routine VL site. A site with a median <0.80 was classified into the non-routine VL sites. VF was defined as VL ≥1000 copies/ml during first-line therapy. Factors associated with VF were analysed using generalized estimating equations with Poisson distribution.

Results: Of 6277 PLHIV starting ART after 2003, 3030 (48%) were from 11 routine VL testing sites and 3247 (52%) were from 10 non-routine VL testing sites. The median follow-up was 9 years (IQR 5–13). The median age was 35 (30–42) years; 68% were male and 3247 (91%) started non-nucleoside reverse-transcriptase inhibitor-based regimen. The median pre-ART CD4 count in PLHIV from routine VL sites was lower compared to non-routine VL sites (144 vs. 156 cells/mm³, p <0.001). Overall, 1021 subsequent VF at a rate of 2.15 (95% CI 2.02–2.29) per 100 person-years (PY). VF was more frequent at non-routine VL sites (adjusted incidence rate ratio 2.85 [95% CI 2.27–3.59]) compared to routine VL sites. Other factors associated with an increased rate of VF were age <50 years and CD4 count <350 cells/mm³. A total of 817 (13%) patients switched to second-line regimen at a rate of 1.44 (95% CI 1.35–1.54) per 100 PY. PLHIV at routine VL monitoring sites were at higher risk of switching than those at non-routine VL sites (adjusted sub-hazard ratio 1.78 95% CI [1.17–2.71]).

Conclusions: PLHIV from non-routine VL sites had a higher incidence of persistent VF and a low switching regimen rate, reflecting possible under-utilized VL testing.

Keywords: HIV; routine viral load testing; Asia; cohort studies; antiretroviral therapy; virological failure

1 | INTRODUCTION

The scale-up of antiretroviral therapy (ART) had a substantial positive impact on the health and quality of life of people living with HIV (PLHIV) and significantly reduced the incidence of HIV infection. There were almost 38 million PLHIV globally at the end of 2020, and 74% of adults living with HIV had access to ART [1]. Increasing treatment cascades towards 90-90-90 UNAIDS targets are indicators of the effective performance of long-term HIV treatment programmes. Achieving viral load (VL) suppression is key to the success of ART at the individual level. Routine VL testing is recommended for treatment monitoring, and to assess whether treatment switches are necessary [2]. According to the World Health Organization (WHO) recommendations, routine VL testing should be conducted 6 and 12 months after ART initiation and every
METHODS

Statistical analysis

Definition and outcomes

Study population

Methods

Statistical analysis

2 METHODS

2.1 Study population

As TAHOD is an adult HIV observational cohort, our analysis included PLHIV aged ≥18 years at ART initiation, from January 2003 to September 2021. There were 21 sites from Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam. The TAHOD cohort contributes to the IeDEA global consortium and has been described previously [12–14]. TAHOD sites are predominantly major HIV referral centres with data collected during routine care [12, 13]. Patients were included if they had started ART with at least three drugs, including an NNRTI or protease inhibitor (PI), and 2–3 nucleoside reverse-transcriptase inhibitors (NRTIs); had at least one VL test in the first year after ART initiation (to allow sufficient follow-up time after treatment); and at least one VL during follow-up. We included all follow-ups based on VL tests during follow-up of first-line therapy as a longitudinal cohort study. Ethics approval was obtained at the sites, TREAT Asia/amfAR (coordinating centre), and the Kirby Institute (data management and statistical analysis centre). A consent waiver was obtained for this study.

2.2 Definition and outcomes

We classified sites according to whether they performed routine VL testing, that is routine VL versus non-routine VL. We defined routine VL by calculating the average number of VL tests for each patient between ART initiation and the last visit date. If the median of the average number of VL tests was above 0.80 per patient per year, the site was classified as routine VL site. If the median was less than 0.80, the site was classified as a non-routine VL site. We utilized 0.80 as the cut of as the WHO’s recommendation for VL testing was done once a year. As there would have been some variability in appointment scheduling and attendance, we utilized 0.80 as the cut-off to allow some flexibility associated with the WHO’s guidelines [2, 14, 15]. In our first analysis, we defined first VF as the first occurrence of VL ≥1000 copies/ml after 6 months on first-line ART. Subsequent VF was defined as any VL ≥1000 copies/ml occurring at any time after the first VF while on first-line ART. The follow-up time of first-line therapy was censored on the date of the last visit or the date of switching to second-line ART for those who have switched. In our second analysis, we defined a switch to second-line ART as a change in a major drug class from NNRTI to PI or vice-versa for at least 6 months, due to treatment failure defined as having at least one VF and used the date of VF closest to the site of switching. PLHIV who did not have VF was confirmed from medical recordings, including immunological and clinical failure for switching to second-line ART. Lost to follow-up (LTFU) was defined as not having a clinic visit in the previous 12 months. The baseline time point was defined as the date of ART initiation.

2.3 Statistical analysis

Baseline characteristics, including demographics, age, income country level, HIV exposure, hepatitis C co-infection, prior AIDS-defining illness, year of ART initiation, first-line ART regimen and pre-ART CD4 count level, were summarized using descriptive statistics for routine VL and non-routine VL sites. The comparison of characteristics between routine VL and non-routine VL sites was performed using Pearson’s Chi-square or Fisher’s exact test, as appropriate, for categorical data and Wilcoxon rank sum test for continuous data. The outcomes rate was calculated by dividing the total number of outcomes by the total number of person-years (PY) of follow-up and expressed as a rate per 100 PY. The associations between routine VL status including with other predictors and VF were presented as incidence rate ratios (IRR) by using generalized estimating equation (GEE) with log link function (Poisson distribution) and exchangeable correlation structure. We used Fine and Gray’s competing risk regression [16] to assess the associations between predictors and switching to second-line ART. Death and LTFU were defined as competing events. Covariates assessed in both GEE and competing risks models included gender, VL routine status, income country level, current age, HIV exposure, HCV status, prior AIDS-defining illness, year of ART initiation, first-line ART regimen and current CD4 count level.

Variables with \( p < 0.10 \) in the univariate analysis were considered for inclusion in multivariate models. Statistical significance was identified using a two-sided \( p \) value less than 0.05. Statistical analysis was performed with SAS version 9.4 (SAS Institute Inc, Cary, NC) and with Stata version 16 (Stata Corp, College Station, TX).
3 RESULTS

3.1 Patient characteristics

A total of 10,789 patients were included. Of these, 4512 patients were excluded for the following reasons: (1) not having yet initiated ART (n = 464, 4%), (2) starting ART with only mono/dual or combination of NNRTI and PI drugs (n = 1104, 10%), (3) initiating ART before 2003 (n = 934, 9%), (4) age < 18 years at ART initiation (n = 15, 0.5%), (5) no sex information (n = 3, 0.5%), (6) assumed to be treatment experienced due to VL < 50 copies/ml at baseline (n = 259, 2%) and (7) no VL measurement after ART initiation (n = 1733, 16%) (Figure 1).

A total of 6277 patients were eligible for the study. There were 3030 (48%) patients from 11 routine VL testing sites which consisted of five sites from high-income countries and six sites from upper-middle-income countries, and 3247 (52%) patients from 10 non-routine VL sites (eight in lower-middle-income countries and two in upper-middle-income countries). The majority were male (65% in non-routine VL, 71% in routine VL, p < 0.001), and the median age at ART initiation was 35 (interquartile range, IQR 30–42) years. We found that 91% started with NNRTI-based ART (99% [58% nevirapine [NVP], 41% efavirenz [EFV]) in lower-middle-income; 95% [47% NVP, 48% EFV] in upper-middle-income; and 60% [11% NVP, 49% EFV] in high-income countries) and 9% started with PI-based ART (1% [0.3% lopinavir [LPV], 0.7% atazanavir [ATV]) in lower-middle-income; 5% [3% LPV, 2% ATV] in upper middle-income; and 40% [24% LPV, 16% ATV] in high-income countries). Most patients had a heterosexual mode of HIV exposure. Thirty-six percent had a prior AIDS diagnosis. The median pre-ART CD4 count in patients from routine VL sites was higher compared to non-routine VL sites (150 vs. 131 cells/mm³, p < 0.001). Forty percent had pre-ART CD4 < 200 cells/mm³ (42% in non-routine VL vs. 38% in routine VL). We found that 42% had pre-ART CD4 < 200 cells/mm³ with advanced HIV disease stage. There was no significant difference in the proportion of pre-ART VL ≥ 1000 copies/ml between non-routine VL and routine VL sites (Table 1).

Overall, the median frequency of VL measurement was 0.75 (0.15–1.24) time/year. For routine VL sites, it was 1.31 (1.17–2.00) time/year, and for non-routine VL sites, it was 0.15 (0.10–0.66) time/year throughout the study period. The median duration on ART during the first-line regimen for non-routine VL sites was 9 (IQR 6–13) years with a total of follow-up 29,671 PYs compared to 9 (IQR 5–13) years with a total of follow-up 27,015 PYs for routine VL sites. For non-routine VL sites, 849 (14%) patients were LTFU (2.86 per 100 PYs; 95% CI 2.68–3.06) and 76 (1%) died (mortality rate 0.26 per 100 PYs; 95% CI 0.20–0.32). The number of LTFU in routine VL was 524 (8%) with 1.94 per 100 PYs; (95% CI 1.78–2.11) and 136 (2%) died (mortality rate 0.50 per 100 PYs; 95% CI 0.43–0.60).

3.2 Virological failure

Overall, 1021 subsequent VF at a rate of 2.15 (95% CI 2.02–2.29) per 100 PYs. We found that the proportion of VF on first-line ART was 16% for non-routine VL and routine VL sites. The crude VF rate of non-routine VL (2.24 [95% CI 2.06–2.44] per 100 PYs) was higher than the crude rate of routine VL sites (2.06 [95% CI 1.89–2.26] per 100 PYs). Figure 2 shows differences between routine VL and non-routine VL in VF rates in the past 3 years after ART initiation.

3.3 Factors associated with frequency of VF

Table 2 shows risk factors associated with VF on first-line ART. We found that in the adjusted multivariate model, VF was more frequent at non-routine VL sites (adjusted
Table 1. Characteristics of HIV-infected patient at ART initiation

| Characteristics                        | Non-routine VL | Routine VL | Total   | p     |
|----------------------------------------|----------------|------------|---------|-------|
| N                                      | 3247 (52%)     | 3030 (48%) | 6277    |       |
| Site                                   | 10             | 11         | 21      |       |
| Income country level, n (%)            |                |            |         | <0.001|
| High income                            | 2579 (79)      | 0 (0)      | 2579 (41)|       |
| Upper to middle income                 | 668 (21)       | 2057 (68)  | 2725 (43)|       |
| Lower middle income                    | 0 (0)          | 973 (32)   | 973 (16) |       |
| Male, n (%)                            | 2096 (65)      | 2164 (71)  | 4260 (68)| <0.001|
| Median (IQR) age, years                | 35 (30–41)     | 36 (30–43) | 35 (30–42)| <0.001|
| 18 to <25, n (%)                       | 227 (7)        | 269 (9)    | 496 (8)  | <0.001|
| 25 to <35, n (%)                       | 1403 (43)      | 1097 (36)  | 2500 (40)|       |
| 35 to <50, n (%)                       | 1345 (41)      | 1342 (44)  | 2687 (43)|       |
| ≥ 50, n (%)                            | 272 (8)        | 322 (11)   | 594 (9)  |       |
| HIV exposure, n (%)                    |                |            |         |       |
| Homosexual                             | 362 (11)       | 996 (33)   | 1358 (22)| <0.001|
| Heterosexual                           | 2333 (72)      | 1757 (58)  | 4090 (65)|       |
| IDU                                    | 94 (3)         | 42 (1)     | 136 (2)  |       |
| Other                                  | 458 (14)       | 235 (8)    | 693 (11)|       |
| Prior AIDS diagnosis, n (%)            |                |            |         | <0.001|
| Yes                                    | 926 (29)       | 1113 (37)  | 2039 (32)|       |
| No                                     | 384 (12)       | 202 (7)    | 586 (9)  |       |
| Unknown                                | 1937 (60)      | 1715 (57)  | 3652 (58)|       |
| Hepatitis B surface antigen status, n (%) |            |            |         | <0.001|
| Negative                               | 1379 (42)      | 1502 (50)  | 2881 (46)|       |
| Positive                               | 148 (5)        | 183 (6)    | 331 (5)  |       |
| Unknown                                | 1720 (53)      | 1345 (44)  | 3065 (49)|       |
| Hepatitis C antibody status, n (%)     |                |            |         | <0.001|
| Negative                               | 1051 (32)      | 1461 (48)  | 2512 (40)|       |
| Positive                               | 299 (9)        | 89 (3)     | 388 (6)  |       |
| Unknown                                | 1897 (58)      | 1480 (49)  | 3377 (54)|       |
| First major regimen, n (%)             |                |            | <0.001   |       |
| NNRTI-based ART                        | 3147 (97)      | 2582 (85)  | 5729 (91)|       |
| PI-based ART                           | 100 (3)        | 448 (15)   | 548 (9)  |       |
| Year of ART initiation, n (%)          |                |            | <0.001   |       |
| 2003–2007                              | 1075 (33)      | 1190 (39)  | 2265 (36)|       |
| 2008–2013                              | 1646 (51)      | 1562 (52)  | 3208 (51)|       |
| 2014–2017                              | 323 (10)       | 193 (6)    | 516 (8)  |       |
| 2017–2021                              | 203 (6)        | 85 (3)     | 288 (5)  |       |
| Pre-ART CD4 count, n (%)               | 2230 (69)      | 1811 (60)  | 4041 (64)|       |
| Median (IQR) CD4 count, cells/mm³      | 156 (56–264)   | 144 (42–246)| 151 (50–253)| 0.001|
| <200                                   | 1360 (42)      | 1165 (38)  | 2525 (40)| <0.001|
| 200–350                                | 595 (18)       | 480 (16)   | 1075 (17)|       |
| ≥350                                   | 275 (8)        | 166 (5)    | 441 (7)  |       |
| Unknown                                | 1017 (31)      | 1219 (40)  | 2236 (36)|       |
| HIV viral load available               | 848 (26)       | 1970 (65)  | 2818 (45)|       |
| Median (IQR) log10 VL, copies/ml       | 5.04 (4.35–5.5)| 4.96 (4.46–5.4)| 4.98 (4.43–5.44)| 0.13|
| HIV viral load ≥1000 copies/ml         | 799 (94)       | 1879 (95)  | 2678 (95)| 0.19|

Note: The comparisons were performed using Pearson’s Chi-square tests or Fisher’s exact test, as appropriate, for categorical data, and Wilcoxon rank sum tests for continuous data. Countries included in the study were Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam. Presented as n (%) for categorical data and median (interquartile range) for continuous data.

Abbreviations: ART, antiretroviral therapy; IDU, injecting drug use; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; VL, viral load.
Table 2. Factors associated with virological failure

| Characteristics                          | Univariate IRR (95% CI) | p      | Multivariate aIRR (95% CI) | p      |
|------------------------------------------|-------------------------|--------|---------------------------|--------|
| VL monitoring status                     |                         |        |                           |        |
| Non-routine VL                           | 2.01 (1.78–2.27)        | <0.001 | 2.85 (2.27–3.59)          | <0.001 |
| Routine VL                               | reference               |        | reference                 |        |
| Income country level                     |                         |        |                           |        |
| Lower middle income                      | 1.74 (1.46–2.07)        | <0.001 | 0.44 (0.32–0.60)          | <0.001 |
| Upper to middle income                   | 1.10 (0.92–1.32)        |        | 0.67 (0.54–0.82)          |        |
| High income                              | reference               |        | reference                 |        |
| Sex                                      |                         |        |                           |        |
| Male                                     | 1.04 (0.91–1.18)        |        | Reference                 | 0.58   |
| Female                                   | reference               |        | Reference                 |        |
| Current age, years                       |                         | <0.001 |                           | <0.001 |
| 18 to <25                                | 2.70 (1.97–3.72)        |        | 3.37 (2.39–4.74)          |        |
| 25 to <35                                | 2.58 (2.17–3.08)        |        | 2.74 (2.28–3.30)          |        |
| 35 to <50                                | 1.69 (1.44–1.98)        |        | 1.79 (1.52–2.12)          |        |
| ≥ 50                                     | Reference               |        | Reference                 |        |
| HIV exposure                             |                         | <0.001 |                           | <0.001 |
| Homosexual                               | reference               |        | Reference                 | 0.80   |
| Heterosexual                             | 1.37 (1.16–1.61)        |        | 1.32 (1.10–1.57)          |        |
| IDU                                      | 2.24 (1.51–3.32)        |        | 1.80 (1.22–2.66)          |        |
| Other                                    | 2.29 (1.85–2.83)        |        | 1.61 (1.30–2.00)          |        |
| Hepatitis C antibody status              |                         | <0.001 |                           |        |
| Negative                                 | reference               |        | Reference                 |        |
| Positive                                 | 1.61 (1.23–2.12)        |        | 0.96 (0.73–1.27)          |        |
| Unknown                                  | 1.57 (1.37–1.79)        |        | 1.54 (1.36–1.75)          |        |
| Prior AIDS diagnosis at ART initiation   |                         | <0.001 |                           |        |
| Yes                                      | Reference               |        | Reference                 | 0.07   |
| No                                       | 1.36 (1.11–1.67)        |        | 1.20 (0.98–1.45)          |        |
| Unknown                                  | 0.85 (0.75–0.97)        |        | 0.85 (0.74–0.97)          |        |
| First major regimen                      |                         | 0.07   |                           | 0.17   |
| NNRTI-based ART                          | 1.22 (0.99–1.51)        |        | 0.94 (0.75–1.17)          |        |
| PI-based ART                             | Reference               |        | Reference                 |        |
| Year of ART initiation                   |                         | 0.07   |                           | 0.59   |
| 2003–2007                                | Reference               |        | Reference                 |        |
| 2008–2013                                | 0.88 (0.77–1.00)        |        | 0.89 (0.78–1.00)          |        |
| 2014–2017                                | 1.14 (0.88–1.46)        |        | 0.97 (0.75–1.26)          |        |
| 2017–2021                                | 1.12 (0.74–1.68)        |        | 0.87 (0.57–1.32)          |        |
| Current CD4 count, cells/mm³             |                         | <0.001 |                           | <0.001 |
| <350                                     | 5.39 (4.74–6.13)        |        | 5.70 (4.97–6.54)          |        |
| ≥350                                     | Reference               |        | Reference                 |        |
| Unknown                                  | 3.54 (3.08–4.07)        |        | 3.33 (2.86–3.87)          |        |

Abbreviations: aIRR, adjusted incidence rate ratio; ART, antiretroviral therapy; 95% CI, 95% confidence interval; IDU, injecting drug use; IRR, incidence rate ratio; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; VL, viral load.

incidence rate ratio [aIRR] 2.85 (95% CI 2.27–3.59) compared to routine VL sites. Patients with current age <25 years (aIRR 3.37, 95% CI 2.39–4.74), age 25 to <35 years (aIRR 2.74, 95% CI 2.28–3.30) and age 35 to <50 years (aIRR 1.79, 95% CI 1.52–2.12) were more likely to have VF when compared with those aged ≥50 years. The current CD4 count <350 cells/mm³ (aIRR 5.70, 95% CI 4.97–6.54) and unknown CD4 count (aIRR 3.33, 95% CI 2.86–3.87) were associated with a higher rate of VF when compared with those who had CD4 count ≥350 cells/mm³. Other factors associated with an increased rate of VF were HIV exposure and income country level.
### 3.4 Switch to second-line ART

A total of 817 (13%) patients switched to a second-line ART regimen according to our definition. Of these, 481 (8%) patients switched due to VF, and 336 (5%) patients switched due to other reasons without evidence of VF. The median duration from VF to switching second-line ART for PLHIV having VL results was 6 (2–23) months (7 [2–25] months in non-routine VL sites and 5 [1–21] months in routine VL sites). In addition, the proportion of those who switched from routine VL sites was higher than non-routine VL sites (18% vs. 9%). The overall rate of switching to second-line ART was 1.44 (95% CI 1.35–1.54) per 100 PYs. The rate for routine VL sites was 1.97 (95% CI 1.81–2.15) per 100 PYs, which was higher than the rate for non-routine VL sites (0.96 [95% CI 0.85–1.08] per 100 PYs, p-value <0.001). The cumulative incidence of switching regimens in routine VL sites at 1, 2 and 3 years were 1.20% (95% CI 0.9–1.7%), 4.0% (95% CI 3.3–4.7%) and 6.2% (95% CI 5.4–7.1%), respectively. For non-routine VL sites, the cumulative incidence of switching regimens at 1, 2 and 3 years were 0.2% (95% CI 0.1–0.5%), 1.3% (95% CI 1.0–1.8%) and 2.7% (95% CI 2.2–3.3%), respectively.

### 3.5 Factors associated with switching to second-line ART

In the adjusted competing risk regression (Table 3), patients at sites with routine VL monitoring were at higher risk of switching compared with those at non-routine VL sites (adjusted sub-hazard ratio [aSHR] 1.78, 95% CI [1.17–2.71]). Switching to second-line regimens was also more likely in high-income countries (aSHR 1.79, 95% CI 1.09–2.96) compared to lower-middle-income countries. Switching regimen rates were higher in men (aSHR 1.23, 95% CI [1.02–1.48]) than in women. Patients aged <25 years (aSHR 11.38, 95% CI 5.63–23.00), age 25 to <35 years (aSHR 5.92, 95% CI 4.71–7.46) and age 35 to <50 years (aSHR 2.32, 95% CI 1.93–2.79) were more likely to switch to second-line ART when compared with those aged ≥50 years. The time updated CD4 count <500 cells/mm$^3$ (aSHR 3.32, 95% CI 2.84–3.89) was associated with a higher rate of switching regimen when compared with those who had CD4 count ≥500 cells/mm$^3$. Other factors associated with increased risk of switching were HIV exposure, year of ART initiation and PI-based regimen initiation.

### 4 DISCUSSION

VL testing can be used as a tool to monitor HIV treatment responses and inform decisions for treatment switching. In our study, the overall crude rate of the first VF after ART initiation at non-routine VL sites was slightly higher than at the routine sites. The rate of subsequent VF during first-line ART was higher in PLHIV at non-routine VL sites compared with PLHIV at routine VL sites. As expected, the rate of switching to second-line in PLHIV at non-routine VL sites was lower than PLHIV at routine VL sites due to our definition of treatment failure, including virological, immunological and clinical failure. The median overall VL testing frequency for the cohort was 0.75 (0.15–1.24) time/year. The VL testing frequency at routine VL sites was higher than at non-routine VL sites. We did not utilize a second confirmatory VL testing to define VF in order to capture all VF that occurred in our cohort. This finding indicated immediately switching to second-line ART after detecting VF for routine VL sites were better clinical management and HIV treatment. Compared to non-routine VL sites, the rate of switching regimens at routine VL was about two times by 3 years of first-line therapy higher in PLHIV at routine VL sites. Moreover, younger aged <25 years were at higher risk of treatment failure and switching to second-line ART compared to those aged ≥25 years old in our study who need to concern for long-term treatment outcome in this age group.

The implementation of routine VL testing is still a major challenge for the Asia-Pacific region since the WHO’s recommendations in 2017 [2]. We found that there was slightly higher rate of first VF among those from routine VL testing sites. This is similar to prior studies in Vietnam [6], Uganda [17] and Thailand [18] where patients with routine monitoring had a higher proportion of VF, but no differences in treatment outcomes. A previous study in Southern Africa shows that the increased VL testing can result in higher rates of viral suppression; however, there was no evidence of a decrease in patients with detectable VL with long-term follow-up [19].

In this study, we focused on the frequency of subsequent VF rate between non-routine VL and routine VL sites during long-term follow-up of first-line therapy. PLHIV at non-routine VL testing sites were at 52% higher persistent VF rate than PLHIV at routine VL testing sites after adjusting with other factors. Non-routine VL testing increased the rate of subsequent VF during follow-up due to a lack of timely follow-up and under-utilized VL testing in resource-limited settings [20–22]. Moreover, non-routine VL was also associated with a long duration of occurring viremia which can cause virologic failure [23, 24]. Our study was intended to better understand the effect of subsequent VF between non-routine VL and routine VL testing sites in long-term follow-up.

We also found that PLHIV from routine VL sites had a higher chance of switching to second-line ART compared to non-routine VL sites. This suggests that routine VL sites were able to identify treatment failure and switch patients promptly to second-line ART.

Prior studies have indicated that scaling up routine VL testing can lead to earlier detection of treatment failure, which allows for immediate switches of ART regimens [7]. In resource-limited settings, switching of ART normally occurred after a single VF, and most patients were switched based on clinical failure without laboratory evidence of treatment failure [5, 10, 25]. When routine VL monitoring is not available, there could be a delay in ART switches resulting in decrease in CD4 cell count. PLHIV with lower CD4 count were at higher risk of VF as well as switching of ART, similar to previous findings from Asia [14] and Sub-Saharan Africa [7]. ART programmes in Sub-Saharan Africa, Asia and Latin America indicated that low pre-ART CD4 counts were associated with switching of ART regimens in sites with and without routine VL testing. Moreover, adherence challenges, the high cost or unavailability of second-line regimens may be the reasons for delayed switching in low/upper middle-income countries [8, 26, 27]. The lack of routine VL testing has also contributed...
### Table 3. Factors associated with switching to second-line regimen

| Characteristics                        | Univariate |    | p  | Multivariate |    | p  |
|----------------------------------------|------------|----|----|--------------|----|----|
|                                        | SHR (95% CI)|    |    | aSHR (95% CI)|    |    |
| VL monitoring status                   |            |    |    | <0.001       |    |    |
| Non-routine VL                         | reference  |    |    | reference    |    |    |
| Routine VL                             | 2.16 (1.87–2.49) |    |    | 1.78 (1.17–2.71) |    | 0.03 |
| Income country level                   |            |    |    | <0.001       |    |    |
| Lower middle income                    | reference  |    |    | reference    |    |    |
| Upper to middle income                 | 0.83 (0.69–1.00) |    |    | 0.38 (0.25–0.58) |    |    |
| High income                            | 4.25 (3.62–4.99) |    |    | 1.79 (1.09–2.96) |    |    |
| Sex                                    |            |    |    | <0.001       |    |    |
| Male                                   | 1.63 (1.38–1.92) |    |    | 1.23 (1.02–1.48) |    | 0.03 |
| Female                                 | reference  |    |    | reference    |    |    |
| Current age, years                     |            |    |    | <0.001       |    | <0.001 |
| 18 to <25                              | 7.47 (4.41–12.64) |    |    | 11.38 (5.63–23.00) |    |    |
| 25 to <35                              | 4.85 (3.96–5.96) |    |    | 5.92 (4.71–7.46) |    |    |
| 35 to <50                              | 1.89 (1.58–2.26) |    |    | 2.32 (1.93–2.79) |    |    |
| ≥ 50                                   | reference  |    |    | reference    |    |    |
| HIV exposure                           |            |    |    | <0.001       |    | <0.001 |
| Homosexual                             | 1.78 (1.53–2.08) |    |    | 0.53 (0.42–0.65) |    |    |
| Heterosexual                           | reference  |    |    | reference    |    |    |
| IDU                                    | 0.57 (0.30–1.11) |    |    | 0.52 (0.26–1.02) |    |    |
| Other                                  | 1.16 (0.92–1.45) |    |    | 0.65 (0.51–0.84) |    |    |
| Hepatitis C antibody status            |            |    |    | 0.04         |    | 0.27 |
| Negative                               | 1.54 (1.09–2.17) |    |    | 1.30 (0.88–1.92) |    |    |
| Positive                               | reference  |    |    | reference    |    |    |
| Unknown                                | 1.45 (1.03–2.04) |    |    | 1.57 (1.07–2.31) |    |    |
| Prior AIDS diagnosis at ART initiation |            |    |    | 0.55         |    |    |
| Yes                                    | 1.08 (0.84–1.37) |    |    | <0.001       |    |    |
| No                                     | reference  |    |    | reference    |    |    |
| Unknown                                | 0.86 (0.68–1.09) |    |    | <0.001       |    |    |
| First major regimen                    |            |    |    | <0.001       |    | <0.001 |
| NNRTI-based ART                        | reference  |    |    | reference    |    |    |
| PI-based ART                           | 3.23 (2.75–3.8) |    |    | 1.34 (1.06–1.68) |    |    |
| Year of ART initiation                 |            |    |    | <0.001       |    | <0.001 |
| 2003–2007                              | reference  |    |    | reference    |    |    |
| 2008–2013                              | 0.90 (0.78–1.03) |    |    | 0.95 (0.82–1.11) |    |    |
| 2014–2017                              | 0.52 (0.36–0.76) |    |    | 0.73 (0.49–1.09) |    |    |
| 2017–2021                              | 0.14 (0.05–0.38) |    |    | 0.31 (0.11–0.87) |    |    |
| Current CD4 count, cells/mm³           |            |    |    | <0.001       |    | <0.001 |
| <350                                   | 3.23 (2.76–3.79) |    |    | 3.32 (2.84–3.89) |    |    |
| ≥350                                   | reference  |    |    | reference    |    |    |
| Unknown                                | 0.20 (0.15–0.28) |    |    | 0.28 (0.20–0.38) |    |    |

Abbreviations: ART, antiretroviral therapy; aSHR, adjusted sub-distribution hazard ratio; 95% CI, 95% confidence interval; IDU, injecting drug use; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SHR, sub-distribution hazard ratio; VL, viral load.

Switching to DTG as per WHO recommendation has been implemented across several countries. Our findings indicate that a small proportion of PLHIV (n = 84) switched to DTG as a second-line regimen during the early period of WHO’s recommendation for DTG use. Most of these PLHIV were from upper middle- and high-income countries. The majority of PLHIV in our study have been using NNRTI-based ART. There is a recommendation to switch to DTG in combination with an optimized NRTIs backbone as the preferred second-line regimen [11]. This is much easier for PLHIV to take than the previous PI-based second-line ART and may also...
encourage more routine VL testing to detect early treatment failure in long-term follow-up.

Our study has strengths and limitations. One of the strengths is to indicate the IRR of subsequent VF between non-routine VL and routine VL testing sites after adjusting with other factors during first-line therapy. There are several limitations to our study. First, we defined VF according to a single VL $\geq 1000$ copies/ml without secondary confirmatory testing. This may overestimate our VF proportions. However, to accommodate sites that do not perform routine VL testing or sites that do not perform confirmatory testing, we believe our definition of VF allowed us to identify VF in our cohort settings appropriately. Second, we did not assess treatment failures associated with routine and non-routine CD4 testing. This would provide an alternative tool to identify risks in treatment outcomes for sites without routine VL testing. Third, as TAHOOD patients were selected to be enrolled based on the likelihood of remaining in care, our results are not generalizable to the wider PLHIV population. Lastly, only a small proportion of PLHIV in our study switched to DTG. We believe that there could be a delay in the application of WHO’s recommended HIV treatment policies in lower/upper middle-income countries due to the varying costs and standard of care [29, 30]. The use of DTG in first-line regimens can increase rapid viral suppression, which may encourage sites to perform routine VL testing in order to detect early treatment failure.

5 | CONCLUSIONS

In conclusion, PLHIV from non-routine VL sites had a higher incidence of persistent VF and low switching regimen rate with delay detecting VF, reflecting possible under-utilized VL testing within these sites. However, the expanding access to routine VL should be continued for HIV treatment monitoring and more common to consider switching ART earlier. Findings suggest that different VL monitoring strategies may have an impact on the time of treatment failure and switch to second-line, as well as the development of drug resistance in long-term treatment.

AUTHORS’ AFFILIATIONS

1Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand; 1HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 2The Kirby Institute, UNSW, Sydney, New South Wales, Australia; 3Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia; 4BJ Government Medical College and Sassoon General Hospital, Pune, India; 5Queen Elizabeth Hospital, Kowloon, Hong Kong SAR; 6National Hospital for Tropical Diseases, Hanoi, Vietnam; 7Chiang Mai University – Research Institute for Health Sciences, Chiang Mai, Thailand; 8Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 9National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; 10National Institute of Child Health and Human Development, Bethesda, MD, USA; 11Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 12Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; 13Beijing Ditan Hospital, Capital Medical University, Beijing, China; 14Faculty of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; 15Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 16National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; 17Institute of Infectious Diseases, University of Wisconsin-Madison, Madison, WI, USA; 18KSF AIDS Foundation, New York, NY, USA; 19Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 20National Center for Global Health and Medicine, Tokyo, Japan; 21Research Institute for Tropical Medicine, Muntinlupa City, Philippines; 22Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; 23Tan Tock Seng Hospital, Singapore; 24Taipei Veterans General Hospital, Taiwan; 25Research Institute for Tropical Medicine, VHS-Infectious Diseases Medical Centre, VHS, Chennai, India; 26National Center for Global Health and Medicine, Tokyo, Japan; 27National Center for Global Health and Medicine, Tokyo, Japan; 28Department of Infectious Diseases, Institute of Health Sciences, Chiang Rai, Thailand; 29Research Institute for Tropical Medicine, VHS-Infectious Diseases Medical Centre, VHS, Chennai, India; 30National Center for Global Health and Medicine, Tokyo, Japan.

COMPETING INTERESTS

The authors declare they have no competing interests.

AUTHORS’ CONTRIBUTIONS

ST designed the study, drafted the initial manuscript, reviewed and critically revised and approved the final manuscript as submitted. AJ was responsible for data aggregation and data management. ST conducted the analysis. AJ and ML advised on the analysis, revised and approved the final manuscript. All authors critically reviewed the manuscript and approved the manuscript for submission.

TAHOOD STUDY MEMBERS

PS Ly*, V Khal, National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; FJ Zhang*, HK Zhao, N Han, Beijing Ditan Hospital, Capital Medical University, Beijing, China; MP Lee*, PCK Li, TS Kwong, TH Li, Queen Elizabeth Hospital, Hong Kong SAR; N Kumarasamy*, C Ezhilarasi, Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS-Infectious Diseases Medical Centre, VHS, Chennai, India; N Pujari*, K Joshi, S Gaikwad, A Chi, Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS-Infectious Diseases Medical Centre, VHS, Chennai, India; S Tan, T Nishijima, National Center for Global Health and Medicine, Tokyo, Japan; JY Choi*, Na S, JM Kim, Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; YM Gani*, NB Rudi, Hospital Sungai Buloh, Sungai Buloh, Malaysia; I Azwa*, A Kannan, Sunpampanalavanar, National Malaya Medical Centre, Kuala Lumpur, Malaysia; R Ditanago*, MK Pasayan, ML Mating, Research Institute for Tropical Medicine, Muntinlupa City, Philippines; YJ Chan*, WW WU, PC WU, E Ke, Taipei Veterans General Hospital, Taipei, Taiwan; OT Ng*, PL Lim, LS Lee, T Yap, Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore (note: OT Ng is also supported by the Singapore Ministry of Health’s (MOH) National Medical Research Council (NMRC) Clinician Scientist Award (MOH-000276)). Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not reflect the views of MOH/NMRC: A Avihingsanon*, S Gatechomp, P Phanuphak, C Phadungphon, HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand; S Kiertiburanakul*, A Phuphukrat, L Chumla, N Sanmeema, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; R Chaowaskit*, T Srisaransha, J Prapatpanatan, K Nuett, Chiang Mai University - Research Institute for Health Sciences, Chiang Mai, Thailand; S Khusuan*, P Payong, P Kantipong, P Kambua, Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; TN Pham*, KV Nguyen, DTH Nguyen, DT Nguyen, National Hospital for Tropical Diseases, Hanoi, Vietnam; CD Do*, AV Ngo, LT Nguyen, Bach Mai Hospital, Hanoi, Vietnam; AH Sohn*, JL Ross*, B Petersen, TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; MG Law*, A Jamaisuk*, D Rupasinge, The Kirby Institute, UNSW Sydney, NSW, Australia; T TAHOOD Steering Committee member.

ACKNOWLEDGEMENTS

The TREAT Asia HIV Observational Database is an initiative of TREAT Asia, a programme of amfAR. The Foundation for AIDS Research, with support from the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases and the Fogarty International Center, as part of the International Epidemiology Databases to Evaluate AIDS (IeDEA: U01AI069907).
FUNDING

The Kirby Institute is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, UNSW Sydney. Interna-
tional SciKU Branding (fSB) is funded by the Faculty of Science, Kaseetsart Univer-
sity.

DISCLAIMER

Data were presented in part at the 4th Asia Pacific AIDS & Co-infections Confer-
ence, June 27–29, 2019, HongKong. The content of this publication is solely the
responsibility of the authors and does not necessarily represent the official views
of any of the governments or institutions mentioned above.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the correspond-
ing author upon reasonable request. Individuals who would like to assess the data
from the IeDEA Asia-Pacific consortium for research purposes may need to submit
a concept proposal in the detail at https://www.iedea.org/.

REFERENCES

1. UNAIDS. Global HIV & AIDS statistics. 2020 [cited 2020 11 September]. Avail-
able from: https://www.unaids.org/en/resources/fact-sheet.
2. WHO. What’s new in treatment monitoring viral load and CD4 testing. Geneva:
WHO; 2017.
3. WHO. HIV treatment and care: what’s new in treatment monitoring: viral load
and CD4 testing. 2017 [updated July 2017; cited 2021 2 November]. Available from:
https://www.who.int/publications/i/item/WHO-HIV-2017.22.
4. El-Sadr WM, Rabkin M, Nkengasong J, Brix DL. Realizing the potential of
routine viral load testing in sub-Saharan Africa. J Int AIDS Soc. 2017;20(Suppl
7):e25010.
5. Awungafac G, Amin ET, Fualefac A, Takah NF, Agyingi LA, Nwobegahay J, et al.
Viral load testing and the use of test results for clinical decision making for HIV
 treatment in Cameroon: an insight into the clinic–laboratory interface. PLoS One.
2018;13(6):e0198686.
6. Pollack TM, Duong TT, Pham TT, Nguyen TD, Libman H, Ngo L, et al. Routine
versus targeted viral load strategy among patients starting antiretroviral in Hanoi,
Vietnam. J Int AIDS Soc. 2019;22(3):e25258.
7. Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al.
Monitoring and switching of first-line antiretroviral therapy in adult treatment
cohorts in sub-Saharan Africa: collaborative analysis. Lancet HIV. 2015;2(7):e271-
8.
8. Sempijja V, Nakigozi G, Gray R, Wawer M, Serwadda D, et al. Rates of
switching to second-line antiretroviral therapy and impact of delayed switching
on immunologic, virologic, and mortality outcomes among HIV-infected adults with
virologic failure in Rakai, Uganda. BMC Infect Dis. 2017;17(1):582.
9. Lakemhewar C, Acharya S, Das M, Meseguer A, Ingole N, et al. Routine
viral load monitoring and enhanced adherence counselling at a public ART centre
in Mumbai, India. PLoS One. 2020;15(5):e0232576.
10. Ya SST, Harries AD, Wai KT, Kyaw NTT, Aung TK, Moi J, et al. Performance
and outcomes of routine viral load testing in people living with HIV newly initiating
ART in the integrated HIV care program in Myanmar between January 2016 and
December 2017. Trop Med Infect Dis. 2020;5(3):140.
11. WHO. Updated recommendations on first-line and second-line antiretrovi-
ral regimens and post-exposure prophylaxis and recommendations on early infant
diagnosis of HIV. Geneva: WHO; 2018.
12. A decade of antiretroviral treatment in Asia: the TREAT Asia HIV
Observational Database Cohort. AIDS Res Hum Retroviruses. 2016;32(8):772-
81.
13. Zhou J, Kumarasamy N, Ditangco R, Kamaruzaman A, Lee CK, Li PC, et al. The
TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir
Immune Defic Syndr. 2005;38(2):174-9.
14. Jung JY, Boettiger D, Wong LW, Lee MP, Kiertiburanakul S, Chaiwarith R,
et al. The treatment outcomes of antiretroviral substitutions in routine clinical set-
tings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD). J
Int AIDS Soc. 2017;20(4):e25016.
15. Jiamsakul A, Karimnia A, Althoff KN, Cesar C, Cortes CP, Davies MA, et al.
HIV viral load suppression in adults and children receiving antiretroviral therapy—results from the IeDEA Collaboration. J Acquir Immune Defic Syndr.
2017;76(3):319-29.
16. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a
competing risk. J Am Stat Assoc. 1999;94:496–509.
17. Okoboi S, Ekwaru PJ, Campbell JD, Egeassa A, King R, Bakanda C, et al. No
differences in clinical outcomes with the addition of viral load testing to CD4 cell
count monitoring among HIV infected participants receiving ART in rural Uganda:
long-term results from the Home Based AIDS Care Project. BMC Public Health.
2016;16:101.
18. Jourdain G, Le Coeur S, Ngo-Giang-Huong N, Traisathit P, Cressy TR,
Fregonesi F, et al. Switching HIV treatment in adults based on CD4 count versus
viral load monitoring; a randomized, non-inferiority trial in Thailand. PLoS Med.
2013;10(8):e1001494.
19. Zaniewski E, Dato Istinenti CH, Chammartin F, Maxwell N, Davies MA, Euvrard
J, et al. Trends in CD4 and viral load testing 2005 to 2018: multi-cohort study of
people living with HIV in Southern Africa. J Int AIDS Soc. 2020;23(7):e25546.
20. Glass TR, Motabab L, Nisaka L, Berendt M, Vanobbergen F, Amstutz A,
et al. The viral load monitoring cascade in a resource-limited setting: a prospective
multicentre cohort study after introduction of routine viral load monitoring in rural
Lesotho. PLoS One. 2019;14(18):e0220337.
21. Peter T, Ellenberger D, Kim AA, Boeras D, Messele T, Roberts T, et al. Early
antiretroviral therapy initiation: access and equity of viral load testing for HIV
treatment monitoring. Lancet Infect Dis. 2017;17(1):e26-9.
22. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of routine viral load test-
ing in resource-poor settings: current and future implementation challenges. Clin
Infect Dis. 2016;62(10):1493-9.
23. Fleming J, Mathews WC, Rutstein RM, Aberg J, Somboonwit C, Cheever LW,
et al. Low-level viremia and virologic failure in persons with HIV infection treated
with antiretroviral therapy. AIDS. 2019;33(13):2005-12.
24. Mesic A, Spina A, Mar HT, Thil P, Decroo T, Lengetl A, et al. Predictors of viro-
logical failure among people living with HIV receiving first line antiretroviral treat-
ment in Myanmar: retrospective cohort analysis. AIDS Res Ther. 2021;18(1):16.
25. Wannigama DL, Amarasinghe M, Hurst C, Phthatrapornjanaphot A, Abe S,
Hongsing P, et al. Tracking COVID-19 with wastewater to understand asympto-
matomic transmission. Int J Infect Dis. 2021;108:296-9.
26. Herman LE, Carmona S, Njhui M, Tempelman HA, Richman DD, Moneyhouse
M, et al. Virological suppression and clinical management in response to viremia
in South African HIV treatment program: a multicenter cohort study. PLoS Med.
2020;17(2):e1003037.
27. Bell Gorrod H, Court R, Schomaker M, Maertens G, Murphy RA. Increased
mortality with delayed and missed switch to second-line antiretroviral therapy in
South Africa. J Acquir Immune Defic Syndr. 2020;84(1):107-13.
28. Bernabe KJ, Siedner M, Tsai AC, Marconi VC, Murphy RA. Detection of
HIV virologic failure and switch to second-line therapy: a systematic review and
meta-analysis of data from sub-Saharan Africa. Open Forum Infect Dis. 2022;9(5):
ofac121.
29. Zheng A, Kumarasamy N, Huang M, Patiel AD, Mayer KH, Rewari BB, et al.
The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as
first-line treatment of HIV infection in India. J Int AIDS Soc. 2018;21(3):e25085.
30. Belay YB, Ali EE, Chung KY, Gebretorkie GB, Sander B. Cost-utility analysis
of dolutegravir- versus efavirenz-based regimens as a first-line treatment in adult
HIV/AIDS patients in Ethiopia. Pharmacoecon Open. 2021;5(4):655-64.